Mayo Clinic researchers have developed a new tool that can estimate a person's risk of developing memory and thinking ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

Chris Hemsworth's touching road trip with his father Craig, who has "early-stage Alzheimer's," is chronicled in a National ...

We break down the current state of frontotemporal dementia, from bvFTD to PPA, and why 'promising' therapies are still far ...

Choose a calm moment, listen first and give the person time to share how they feel. Here are some other tips on how to help a ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

An oral GLP-1 drug from Novo Nordisk failed to delay the progression of Alzheimer's disease in a pair of clinical trials, dealing a setback to the Danish drug giant's hopes of expanding the market for ...

Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s ...

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

Neuropsychologist April Krowel describes the condition, which affects roughly one in five people with dementia, as 'a ...

"While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer's disease, the extensive body of ...

Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or ...